An in-silico approach to design potential siRNAs against the ORF57 of Kaposi's sarcoma-associated herpesvirus.

Q2 Agricultural and Biological Sciences
Genomics and Informatics Pub Date : 2021-12-01 Epub Date: 2021-12-31 DOI:10.5808/gi.21057
Anisur Rahman, Shipan Das Gupta, Md Anisur Rahman, Saheda Tamanna
{"title":"An in-silico approach to design potential siRNAs against the ORF57 of Kaposi's sarcoma-associated herpesvirus.","authors":"Anisur Rahman, Shipan Das Gupta, Md Anisur Rahman, Saheda Tamanna","doi":"10.5808/gi.21057","DOIUrl":null,"url":null,"abstract":"<p><p>Kaposi's sarcoma-associated herpesvirus (KSHV) is one of the few human oncogenic viruses, which causes a variety of malignancies, including Kaposi's sarcoma, multicentric Castleman disease, and primary effusion lymphoma, particularly in human immunodeficiency virus patients. The currently available treatment options cannot always prevent the invasion and dissemination of this virus. In recent times, siRNA-based therapeutics are gaining prominence over conventional medications as siRNA can be designed to target almost any gene of interest. The ORF57 is a crucial regulatory protein for lytic gene expression of KSHV. Disruption of this gene translation will inevitably inhibit the replication of the virus in the host cell. Therefore, the ORF57 of KSHV could be a potential target for designing siRNA-based therapeutics. Considering both sequence preferences and target site accessibility, several online tools (i-SCORE Designer, Sfold web server) had been utilized to predict the siRNA guide strand against the ORF57. Subsequently, off-target filtration (BLAST), conservancy test (fuzznuc), and thermodynamics analysis (RNAcofold, RNAalifold, and RNA Structure web server) were also performed to select the most suitable siRNA sequences. Finally, two siRNAs were identified that passed all of the filtration phases and fulfilled the thermodynamic criteria. We hope that the siRNAs predicted in this study would be helpful for the development of new effective therapeutics against KSHV.</p>","PeriodicalId":36591,"journal":{"name":"Genomics and Informatics","volume":"19 4","pages":"e47"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752988/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genomics and Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5808/gi.21057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Agricultural and Biological Sciences","Score":null,"Total":0}
引用次数: 0

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is one of the few human oncogenic viruses, which causes a variety of malignancies, including Kaposi's sarcoma, multicentric Castleman disease, and primary effusion lymphoma, particularly in human immunodeficiency virus patients. The currently available treatment options cannot always prevent the invasion and dissemination of this virus. In recent times, siRNA-based therapeutics are gaining prominence over conventional medications as siRNA can be designed to target almost any gene of interest. The ORF57 is a crucial regulatory protein for lytic gene expression of KSHV. Disruption of this gene translation will inevitably inhibit the replication of the virus in the host cell. Therefore, the ORF57 of KSHV could be a potential target for designing siRNA-based therapeutics. Considering both sequence preferences and target site accessibility, several online tools (i-SCORE Designer, Sfold web server) had been utilized to predict the siRNA guide strand against the ORF57. Subsequently, off-target filtration (BLAST), conservancy test (fuzznuc), and thermodynamics analysis (RNAcofold, RNAalifold, and RNA Structure web server) were also performed to select the most suitable siRNA sequences. Finally, two siRNAs were identified that passed all of the filtration phases and fulfilled the thermodynamic criteria. We hope that the siRNAs predicted in this study would be helpful for the development of new effective therapeutics against KSHV.

Abstract Image

Abstract Image

Abstract Image

设计针对卡波西肉瘤相关疱疹病毒 ORF57 的潜在 siRNAs 的一种室内方法。
卡波西肉瘤相关疱疹病毒(KSHV)是少数几种人类致癌病毒之一,可导致多种恶性肿瘤,包括卡波西肉瘤、多中心卡斯特曼病和原发性渗出性淋巴瘤,尤其是在人类免疫缺陷病毒患者中。目前可用的治疗方案并不能始终阻止这种病毒的入侵和传播。近来,基于 siRNA 的疗法正逐渐取代传统药物,因为 siRNA 几乎可以针对任何感兴趣的基因进行设计。ORF57 是 KSHV 裂解基因表达的关键调控蛋白。中断该基因的翻译将不可避免地抑制病毒在宿主细胞中的复制。因此,KSHV的ORF57可能是设计基于siRNA疗法的潜在靶点。考虑到序列偏好和靶点可及性,研究人员利用几种在线工具(i-SCORE Designer、Sfold web server)预测了针对 ORF57 的 siRNA 引导链。随后,还进行了脱靶过滤(BLAST)、保守性测试(fuzznuc)和热力学分析(RNAcofold、RNAalifold 和 RNA Structure 网络服务器),以选择最合适的 siRNA 序列。最后,我们确定了两个 siRNA,它们通过了所有过滤阶段,并符合热力学标准。我们希望本研究预测的 siRNA 能有助于开发新的有效的 KSHV 治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Genomics and Informatics
Genomics and Informatics Agricultural and Biological Sciences-Ecology, Evolution, Behavior and Systematics
CiteScore
1.90
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信